Key result
Systemic chemotherapy yielded partial/complete response in 17% and stable disease in 25% of patients with advanced liposarcoma, with a median overall survival of 13.0 months.
Why the study?
What are the clinical outcomes and prognostic factors for patients with advanced liposarcoma treated in a tertiary referral center?
Population
100 patients with inoperable or metastatic dedifferentiated liposarcoma, myxoid/round cell liposarcoma, and…
Design
Cohort
Authors
Loading...
Highlights limited chemotherapy benefit in advanced liposarcoma; leaves open optimal multimodal strategies including metastasectomy.
Cohort (n=100)
No
What are the clinical outcomes and prognostic factors for patients with advanced liposarcoma treated in a tertiary referral center?
Advanced liposarcoma has a poor prognosis and low response rates to chemotherapy, but metastasectomy and disease control with first-line chemotherapy are associated with better overall survival.
Langmans et al. (2019) conducted a cohort in Advanced Liposarcoma (n=100). Systemic chemotherapy was evaluated on Overall survival. Systemic chemotherapy yielded partial/complete response in 17% and stable disease in 25% of patients with advanced liposarcoma, with a median overall survival of 13.0 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: